alkylate

(redirected from alkylating)
Also found in: Medical, Encyclopedia.

al·kyl·ate

 (ăl′kə-lāt′)
tr.v. al·kyl·at·ed, al·kyl·at·ing, al·kyl·ates
To add one or more alkyl groups to (a compound).

al′kyl·a′tion (-kə-lā′shən) n.

alkylate

(ˈælkɪˌleɪt)
vb (tr)
to bring (an alkyl group) into a compound

al•kyl•ate

(ˈæl kəˌleɪt)

v.t. -at•ed, -at•ing.
to introduce an alkyl group into (a compound).
[1885–90]
Translations
alkylat
References in periodicals archive ?
1, a novel topoisomerase inhibitor; EDO-S101, a novel, first-in-class alkylating deacetylase inhibitor and EDO-B776 and EDO-B278, two late pre-clinical stage antibody-drug conjugates.
The disease must be refractory to both rituximab and an alkylating agent.
He begins with the reagents and processes: alkylating agents, acylating agents, nitration and nitrosylation, oxidation, and modifying proteins with reducing agents.
Our study showed that these alkylating agents are present at levels sufficient to cause DNA damage and could potentially have adverse implications to human health, particularly in the case of the development of oral cancer for BQ chewers," they said.
Synthesis of quinonemethide, its reactivity and electrochemistry of purine-like imidazo[4,5-g]quinazoline reductive alkylating agents possessing a leaving group at the 6a-position were studied.
Modifying agents include alkylating, amidating, esterification, metallation, phosphorylating, sulfonating, oxidizing, and reducing agents.
Their topics include human biotransformation, analytical tools and approaches for metabolic identification in drug metabolism, the unanticipated loss of N2 from novel DNA alkylating agent laromustine by collision-induced dissociation, and strategies for detecting reactive intermediates in drug discovery and development.
Titled "Bendamustine: A Novel Cytotoxic Agent for Hematologic Malignancies," it notes that bendamustine hydrochloride has a chemical structure containing alkylating nitrogen mustard, contributing to its cytotoxic properties.
Overall, the literature suggests that 34% of females who undergo chemotherapy develop ovarian failure, though alkylating agents such as cyclophosphamide are four times as toxic to the ovaries as other agents, Dr.
Currently, the drug is approved to treat the disease in patients that have been treated with an alkylating agent and have failed fludarabine therapy.
Osteoporosis is one such potential complication that can result from treatment with alkylating agents and the steroids that are often given with chemotherapy.
The drug is currently not approved for the treatment of multiple sclerosis but is indicated for treating B-cell chronic lymphocytic leukemia in patients who have been treated with alkylating agents and who have failed fludarabine therapy.